# Clinical Cases: Apoptosis and Cell Death

## Case 1: Follicular Lymphoma (BCL2 Overexpression)

### Clinical Image
![Follicular Lymphoma](case_01_image.jpg)
*Source: [Wikipedia - Follicular lymphoma](https://en.wikipedia.org/wiki/Follicular_lymphoma) - CC BY-SA 3.0*

### Case Presentation
A 62-year-old woman presents with painless cervical lymphadenopathy noticed while showering. She has no fever, night sweats, or weight loss. Physical examination reveals multiple rubbery, non-tender lymph nodes in the cervical, axillary, and inguinal regions. CT scan shows widespread lymphadenopathy above and below the diaphragm. Excisional lymph node biopsy reveals follicular lymphoma grade 1-2. Cytogenetic analysis demonstrates the characteristic t(14;18)(q32;q21) translocation. This translocation places the BCL2 gene under control of the immunoglobulin heavy chain enhancer, resulting in marked overexpression of the anti-apoptotic Bcl-2 protein. The hematologist explains that normally, B cells in germinal centers that fail to successfully rearrange their immunoglobulin genes or that produce self-reactive antibodies undergo apoptosis. With Bcl-2 overexpression, these cells resist apoptosis and accumulate, eventually acquiring additional mutations that drive lymphomagenesis. Given her asymptomatic, advanced-stage disease, a watch-and-wait approach is initially adopted. Years later, when she develops symptoms, she is treated with rituximab plus bendamustine. More recently, venetoclax, a BH3 mimetic that specifically inhibits Bcl-2, has become available for Bcl-2-dependent malignancies.

### Key Learning Points
- Bcl-2 is an anti-apoptotic protein that prevents mitochondrial outer membrane permeabilization (MOMP) by sequestering pro-apoptotic Bax and Bak; its overexpression blocks the intrinsic apoptotic pathway
- The t(14;18) translocation, discovered in follicular lymphoma, established that blocking cell death (not just promoting proliferation) is an oncogenic mechanism
- Understanding Bcl-2's mechanism led to development of BH3 mimetics like venetoclax, which bind Bcl-2 and release Bax/Bak to trigger apoptosis, representing targeted restoration of cell death

---

## Case 2: Autoimmune Lymphoproliferative Syndrome (Fas Deficiency)

### Clinical Image
![ALPS Splenomegaly](case_02_image.jpg)
*Source: [Wikipedia - Autoimmune lymphoproliferative syndrome](https://en.wikipedia.org/wiki/Autoimmune_lymphoproliferative_syndrome) - CC BY-SA 3.0*

### Case Presentation
A 7-year-old boy is referred for evaluation of chronic lymphadenopathy and splenomegaly present since age 2. He has had multiple episodes of immune thrombocytopenia and autoimmune hemolytic anemia requiring steroids. Physical examination reveals massive splenomegaly and diffuse non-tender lymphadenopathy. Flow cytometry reveals an expanded population of double-negative T cells (CD3+CD4-CD8-), comprising 8% of lymphocytes (normally <1.5%). Genetic testing identifies a heterozygous mutation in FAS (TNFRSF6). The immunologist explains that Fas is a death receptor critical for eliminating activated and autoreactive lymphocytes. When FasL on one lymphocyte engages Fas on another, it triggers formation of the death-inducing signaling complex (DISC), activating caspase-8 and initiating apoptosis. Without functional Fas, lymphocytes that should be eliminated persist, accumulating as double-negative T cells and causing lymphoproliferation and autoimmunity. This is autoimmune lymphoproliferative syndrome (ALPS). Management includes treatment of autoimmune cytopenias, surveillance for lymphoma (elevated risk), and consideration of sirolimus which can reduce lymphoproliferation. He eventually requires splenectomy for refractory cytopenias.

### Key Learning Points
- The extrinsic apoptotic pathway is triggered by death receptor engagement (Fas-FasL, TRAIL-DR4/5); this pathway is essential for immune homeostasis and eliminating autoreactive lymphocytes
- ALPS demonstrates the physiological importance of apoptosis: defective Fas signaling prevents normal lymphocyte death, causing accumulation of abnormal lymphocytes and autoimmunity
- The accumulation of double-negative T cells (CD3+CD4-CD8-) is a hallmark diagnostic feature and reflects cells that should have been eliminated after activation

---

## Case 3: Venetoclax for Chronic Lymphocytic Leukemia (BH3 Mimetic Therapy)

### Clinical Image
![CLL Blood Smear](case_03_image.jpg)
*Source: [Wikipedia - Chronic lymphocytic leukemia](https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia) - CC BY-SA 3.0*

### Case Presentation
A 72-year-old man with chronic lymphocytic leukemia (CLL) has progressed through multiple prior therapies including chemoimmunotherapy and ibrutinib. His disease has acquired a TP53 deletion, associated with treatment resistance. He is started on venetoclax, a selective Bcl-2 inhibitor, combined with rituximab. The oncologist explains that CLL cells are heavily dependent on Bcl-2 for survival. Venetoclax is a BH3 mimetic, a small molecule designed to mimic the BH3 domain of pro-apoptotic proteins. It binds to the hydrophobic groove of Bcl-2 where pro-apoptotic proteins normally bind, displacing sequestered Bax and Bak. The freed Bax and Bak oligomerize, causing MOMP, cytochrome c release, apoptosome formation, and caspase activation, restoring the apoptotic pathway. He is warned about tumor lysis syndrome (TLS) due to rapid cell death and started on dose ramp-up with aggressive hydration and monitoring. He achieves deep remission with undetectable minimal residual disease. This case demonstrates how understanding apoptosis mechanisms has led to effective targeted therapies that exploit cancer cell dependencies.

### Key Learning Points
- BH3 mimetics like venetoclax work by binding anti-apoptotic Bcl-2 family proteins, displacing sequestered pro-apoptotic Bax and Bak to restore the intrinsic apoptotic pathway
- Cancer cells often become "addicted" to anti-apoptotic proteins for survival; targeting these dependencies can be therapeutically effective even in chemotherapy-resistant disease
- Tumor lysis syndrome risk with venetoclax reflects the rapid, massive cell death induced by restoring apoptosis; careful dose escalation and monitoring are required